J.P. Morgan analyst Cory Kasimov maintained a Buy rating on Seagen on Thursday, setting a price target of $177, which is approximately 6.73% above the present share price of $165.84.
Kasimov expects Seagen to post earnings per share (EPS) of $3.65 for the first quarter of 2021.
The current consensus among 13 TipRanks analysts is for a Moderate Buy rating of shares in Seagen, with an average price target of $191.42.
The analysts price targets range from a high of $254 to a low of $158.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $1.06 billion and a net profit of $638.19 million. The company's market cap is $29.68 billion.
According to TipRanks.com, J.P. Morgan analyst Cory Kasimov is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 21.2% and a 55.00% success rate.
Seattle Genetics (NASDAQ:SGEN), Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.